Abstract
Introduction
It is well established that a sedentary lifestyle, in concert with a long-term imbalance of energy uptake and expenditure, is a major cause for the alarming high incidence of type 2 diabetes mellitus in western countries. Consistently, the suggested initial antidiabetic therapy consists of a change in diet together with an augmentation of the patient´s physical activities. Physical exercise increases the need for fat and carbohydrates and improves glycemic control and dyslipidemia in diabetes patients.
1,2 Individualized training programs for type 2 diabetes patients were established to meet this therapeutic option.
3
In response to a failure of lifestyle changes to combat diabetes progression, administration of glitazones, also referred to as thiazolidinediones (TZD), is an additional therapeutic option. Glitazones improve hyperglycemia through activation of the nuclear peroxisome proliferatoractivated receptor γ (PPARγ). Pioglitazone, a member of the TZD family, also ameliorates the lipid metabolism as assessed by a decrease in low-density lipoproteins and an increase in high-density lipoproteins. 4, 5 As far as both exercise and TZD medication improving the metabolic conditions of a type 2 diabetes patient, data are contradictory: In an animal model, a combination effect of troglitazone treatment and voluntary running was not detected. 6 However, Reusch et al. 7 assumed that the pleiotropic effects of TZDs may act beneficially on exercise capacity and that TZDs may improve the metabolic control synergistically with physical exercise. Furthermore, rosiglitazone improves exercise capacity but the underlying mechanisms remain to be elucidated. 8 Only insufficient data are available in regard to a combination of glitazone therapy and physical exercise under daily routine conditions. This observational trial analysis aims to fill this gap. We collected socio-demographic and metabolic data from type 2 diabetes patients starting pioglitazone therapy and analyzed it in respect to their physical exercise activities at baseline and after 20 weeks of pioglitazone medication.
Observational Trial Design and Methods

Study Design
The IRIS III study was designed as a multicenter observational drug-monitoring trial with an entire trial duration of 12 months and an individual observational period of about 20 weeks following the regulations of Good Clinical Practice. The open-label prospective observational study was approved by the Independent Ethical Review Board of Freiburg, Germany. The design did allow conduct under daily routine conditions. Main inclusion criteria were glitazone-naïve patients with type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) value between 6.6 and 9.9%. Main exclusion criteria were all the contraindications as defined in the instructions for the use of pioglitazone. The patients received pioglitazone in addition to their current antidiabetic therapy. Patients receiving insulin therapy were excluded. Pioglitazone was given to the patients orally before breakfast in the morning (fasting period >8 hours).
The following observation parameters were collected at baseline and after 20 weeks of treatment: fasting blood glucose, lipid profile [triglyceride, high-density lipoproteins (HDL), low-density lipoproteins (LDL)], weight, body mass index (BMI), and blood pressure. Physical activity was assessed during anamnesis and was classified individually as "never," "sometimes," or "regularly." Additionally, the measurement of HbA1c was Abstract cont.
Conclusions:
These observational results, obtained from a nonselected patient population under daily routine conditions, confirm that the benefits of pioglitazone treatment on glycemic control, lipid metabolism, and blood pressure are independent from physical activity. Exercise has a positive influence on insulin sensitivity, but pioglitazone shows additional favorable effects and is, therefore, recommended for use independently from the activity level of the patients.
performed in a central laboratory at baseline and at endpoint. HbA1c was measured colorimetrically with an automatic glycohemoglobin analyzer (Adams™ A1c) according to the manufacturer's instructions (HA-8160 kit, Menarini Diagnostics, Neuss, Germany).
Data Analysis
For the final analysis, patients were stratified into three categories according to their physical activity. As appropriate, baseline values were adjusted to eliminate significant differences. Statistical analysis was performed using standard descriptive statistics and appropriate parametrical and nonparametrical tests. Calculations were made with the SPSS statistical package (version 9.0, SPSS Inc., Chicago, IL). The means of the variables were compared using a two-sided Student´s t test and MannWhitney´s U test. Results with p values less than 0.05 were considered statistically significant. The Spearman´s rank test was used to calculate the correlation coefficients. Because this study was designed as an observational trial, all p values are to be interpreted in an exploratory sense.
Results
This observational trial included 2092 patients. The study population consisted of 988 female and 1104 male patients. On average (± SD), the patients were 63 ± 10 years old, had been suffering from diabetes for 6.1 ± 5.0 years, and had an initial BMI of 30.5 ± 5.4 kg/m 2 . Information about physical exercise activities was available from 1313 patients. From 15 patients of this group, no further laboratory or clinical data were reported. Thus, 1298 patients with complete data sets were included in the final analysis. The entire analysis group consisted of 622 women and 676 men (in mean, height: 169.1 ± 8.7 cm, age: 63.1 ± 10.3 years, diabetes duration: 6.6 ± 5.0 years), and the physical activity subgroups did not differ considerably at baseline (never, height: 168.5 ± 8.7 cm, age: 62.8 ± 11.5 years, diabetes duration: 6.8 ± 4.7 years; sometimes, height: 169.3 ± 8.6 cm, age: 63.0 ± 9.9 years, diabetes duration: 6.3 ± 4.7 years; regularly, height: 169.6 ± 9.1 cm, age: 63.6 ± 10.0 years, diabetes duration: 7.5 ± 6.1 years). We further stratified the entire study cohort to compare the results of pioglitazone treatment on laboratory markers according to the subject´s physical activity. Baseline values for fasting blood glucose, HDL, weight, BMI, and diastolic blood pressure were adjusted to eliminate the significant differences prior to any analyses. The improvement in each parameter is given in Table 2 . The effects of pioglitazone treatment on glycemic control and on the lipid profile were independent of the physical activity of the patients, whereas the positive effects on insulin sensitivity were related to exercise and were additionally supported by pioglitazone treatment.
Discussion
This study investigated the impact of pioglitazone treatment on metabolic markers in type 2 diabetes patients under daily routine conditions. Comparative data of glycemic control, lipid profile, and clinical measures were obtained before and after 20 weeks of pioglitazone administration. This study confirmed the well-known potency of pioglitazone to improve the metabolic situation with respect to glycemic control hypertension and the overall lipid profile.
9-14
Data were further stratified according to the patient´s physical activity into the following three activity categories: "never," "sometimes," and "regularly." Analysis of the results in relation to physical exercise revealed the different effects of physical activity and pioglitazone treatment. As expected, both blood glucose and hypertension are influenced beneficially by exercise. It is well established that regular physical activity yields reduced fasting glucose levels [15] [16] [17] and decreased systolic blood pressure. 1, [17] [18] [19] [20] This study confirmed these results and emphasized the fundamental role of physical exercise in the treatment of diabetes. However, it is noteworthy that pioglitazone treatment has a synergistic effect to exercise and can improve glucose levels and blood pressure to a greater extent than physical activity alone. The impact of oral antidiabetic treatment in concert with exercise on both lowering blood glucose 21 and improving cardioprotective markers 22 has also been shown for rosiglitazone treatment. These data are in line with an interventional study showing that rosiglitazone amplifies some benefits of lifestyle intervention, including physical activity in poorly controlled type 2 diabetes patients. a Data are given as mean values ± standard of deviation. Significant changes are indicated by a p value in bold numbers. All data are to be interpreted as reductions, except HDL, which increased after the observational period, and the weight gain in the "regular physical activity" group.
23
Glitazones, like pioglitazone, effectively improve the insulin sensitivity of patients with metabolic syndrome.
24
This clinical effect is based on its PPARγ-activating properties. 4 Additionally, moderate exercise also increases insulin sensitivity. 25 However, troglitazone failed to increase insulin sensitivity in concert with physical activities. 6 In this study, the recently published IRIS II score 26 was used to define insulin sensitivity. The score uses an algorithm that takes metabolic markers into account for a high specific insulin resistance assessment. The effect of pioglitazone treatment on the reduction of insulin resistance occurred in each subgroup. Physical activity alone significantly increased insulin sensitivity according to the IRIS II score in our study. Although additional pioglitazone treatment supported this effect in all three subgroups, the most impressive beneficial effect could be observed in patients not performing exercise. Results from our observational trial are in line with a study showing the beneficial effects of a combination of physical activity and pioglitazone treatment under controlled clinical trial conditions.
27
One metabolic difference between the effects of the two commercially available glitazones, pioglitazone and rosiglitazone, is the improvement in the patient´s lipidemic profile.
28
Pioglitazone reduces triglycerides and LDL cholesterol and increases HDL cholesterol to a significantly greater extent than rosiglitazone. Some studies revealed an improvement of the lipid profile in response to regular exercise. 17, 29, 30 Furthermore, exercise is considered to hamper LDL oxidation. 31 In contrast to other studies, this trial analyzed a nonselected patient cohort under clinical routine conditions. In all three exercise subgroups, a comparable effect on the lipid profile could be reported. Therefore, the observed improvement can be traced back to the effects of the pioglitazone treatment alone.
Data of this observational trial show a considerable degree of variations, resulting in the observed lack of correlation between physical activity given in an ordinal scale and metabolic improvements by glitazone treatment. The heterogeneity of baseline and outcome data reflects the situation in clinical routine practice. To confirm the observations reported here, current trials are investigating the concerted benefits of pioglitazone and exercise in more detail. In summary, this study confirmed earlier results of metabolic improvements by a pioglitazone therapy under daily routine conditions and demonstrated that pioglitazone treatment has clinical benefits that are independent of the physical activities of the patient.
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